• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer.

作者信息

Yan Weigang, Zhou Yi, Zhou Zhien, Ji Zhigang, Li Hanzhong

机构信息

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.

出版信息

Lancet Oncol. 2017 Apr;18(4):e187. doi: 10.1016/S1470-2045(17)30170-5.

DOI:10.1016/S1470-2045(17)30170-5
PMID:28368249
Abstract
摘要

相似文献

1
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer.帕德博芬血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究
Lancet Oncol. 2017 Apr;18(4):e187. doi: 10.1016/S1470-2045(17)30170-5.
2
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.帕利泊芬血管靶向光动力疗法与主动监测治疗低危前列腺癌男性患者（CLIN1001 PCM301）：一项开放标签、3 期、随机对照临床试验。
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.
3
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply.帕德立卟吩血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比——作者回复
Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8.
4
Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.回复：Padeliporfin 血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究（CLIN1001 PCM301）：一项开放标签、3期随机对照试验
J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029. Epub 2017 May 10.
5
Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial.关于“Padeliporfin血管靶向光动力疗法与低风险前列腺癌男性主动监测的对比研究（CLIN1001 PCM301）：一项开放标签、3期、随机对照试验”的评论
Urology. 2017 Jun;104:7-8. doi: 10.1016/j.urology.2017.03.020. Epub 2017 Mar 22.
6
Photodynamic therapy for prostate cancer - A narrative review.光动力疗法治疗前列腺癌——叙述性综述。
Photodiagnosis Photodyn Ther. 2021 Mar;33:102158. doi: 10.1016/j.pdpdt.2020.102158. Epub 2020 Dec 19.
7
Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.帕德博芬（WST11）血管靶向光动力疗法的适应证扩展：前列腺癌拉丁美洲多中心研究结果
Actas Urol Esp (Engl Ed). 2018 Dec;42(10):632-638. doi: 10.1016/j.acuro.2018.02.009. Epub 2018 Apr 23.
8
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.使用TOOKAD®可溶性制剂进行的血管靶向光动力疗法治疗局限性前列腺癌：治疗程序的标准化
World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.
9
Prostate cancer: Light, camera, action - photodynamic therapy for low-risk disease.前列腺癌：灯光、镜头、开拍——低风险疾病的光动力疗法
Nat Rev Urol. 2017 Mar;14(3):134. doi: 10.1038/nrurol.2017.1. Epub 2017 Jan 10.
10
Androgen Receptor Targeted Conjugate for Bimodal Photodynamic Therapy of Prostate Cancer in Vitro.用于前列腺癌体外双模态光动力治疗的雄激素受体靶向共轭物
Bioconjug Chem. 2015 Aug 19;26(8):1662-71. doi: 10.1021/acs.bioconjchem.5b00261. Epub 2015 Jul 2.

引用本文的文献

1
Chemotherapeutic Activity of Imidazolium-Supported Pd(II) -Vanillylidene Diaminocyclohexane Complexes Immobilized in Nanolipid as Inhibitors for HER2/neu and FGFR2/FGF2 Axis Overexpression in Breast Cancer Cells.固定在纳米脂质中的咪唑鎓负载的Pd(II)-香草亚基二氨基环己烷配合物作为乳腺癌细胞中HER2/neu和FGFR2/FGF2轴过表达抑制剂的化疗活性
Pharmaceuticals (Basel). 2023 Dec 11;16(12):1711. doi: 10.3390/ph16121711.
2
Focal therapy, time to join the multi-disciplinary team discussion?聚焦治疗，是时候加入多学科团队讨论了吗？
Transl Androl Urol. 2020 Jun;9(3):1526-1534. doi: 10.21037/tau.2019.09.30.
3
A Tumor Vascular-Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia.
一种诱导并利用缺氧的肿瘤血管靶向互锁三模态纳米系统。
Adv Sci (Weinh). 2018 May 28;5(8):1800034. doi: 10.1002/advs.201800034. eCollection 2018 Aug.
4
Combination of MPPa-PDT and HSV1-TK/GCV gene therapy on prostate cancer.MPPa光动力疗法与HSV1-TK/GCV基因疗法联合治疗前列腺癌
Lasers Med Sci. 2018 Feb;33(2):227-232. doi: 10.1007/s10103-017-2331-6. Epub 2018 Jan 6.